ClearPoint Neuro Announces FDA Clearance of the SmartFrame Array

By A Mystery Man Writer

Next Generation Neuro Navigation System Designed for Use in Both the MRI Suite and Operating Room ClearPoint SmartFrame Array™ Version 1.1 ClearPoint SmartFrame Array™ Version 1.1 SOLANA BEACH, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that it has received FDA clearance for version 1.1 of its next generation SmartFrame Array Neuro Navi
Next Generation Neuro Navigation System Designed for Use in Both the MRI Suite and Operating Room ClearPoint SmartFrame Array™ Version 1.1 ClearPoint SmartFrame Array™ Version 1.1 SOLANA BEACH, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that it has received FDA clearance for version 1.1 of its next generation SmartFrame Array Neuro Navi
Next Generation Neuro Navigation System Designed for Use in Both the MRI Suite and Operating Room ClearPoint SmartFrame Array™ Version 1.1 ClearPoint

FDA Clears Turner Imaging Systems' Smart-C Mini C-arm

ClearPoint Neuro, Inc. on LinkedIn: Finalists Announced - CEO of the Year Awards 2022

ClearPoint Neuro, Inc. Announces First Procedure Utilizing ClearPoint® 2.0 Software in Europe

ClearPoint Neuro, Inc. Announces First-in-Human Cases of the SmartFrame Array™ Neuro Navigation System and Software

CLS, Clinical Laserthermia Systems AB (ej officiell), Clearpoint Neuro analys

Stock Market News 2022-04-28

ClearPoint Neuro: The New Neurosurgical Platform Of Choice (NASDAQ:CLPT)

Shusen Liu named chief medical officer of GenomiCare Biotechnology - The Cancer Letter

Press Releases :: ClearPoint Neuro, Inc. (CLPT)